Last reviewed · How we verify
NCT04536129
Effects of Topical Low Dose Preservative-free Hydrocortisone on Intraocular Pressure
NA trial testing Hydrocortisone (CORTIVIS ®) in Ocular Surface Disease in 90 participants. Completed in 4 March 2020.
4 March 2020
Quick facts
| Lead sponsor | University of Molise |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | non randomized |
| Design | parallel |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 4 November 2019 |
| Primary completion | 4 March 2020 |
| Estimated completion | 4 March 2020 |
| Sites | 1 location across Italy |
Drugs / interventions tested
- Hydrocortisone (CORTIVIS ®) — full drug profile →
Conditions studied
- Ocular Surface Disease — all drugs for Ocular Surface Disease →
- Glaucoma — all drugs for Glaucoma →
Sponsor
University of Molise
Who can join
Adults 18 to 80, any sex, with Ocular Surface Disease or Glaucoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Evaluation of the safety and efficacy of hydrocortisone eye drops in the treatment of OSD (ocular surface disease) patients with and without glaucoma.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Effects of topical low-dose preservative-free hydrocortisone on intraocular pressure in patients affected by ocular surface disease with and without glaucoma.
Filippelli M, dell'Omo R, Gelso A, Rinaldi M, et al · · 2022 · cited 3× · PMID 34406502 · DOI 10.1007/s00417-021-05345-3
Verify or expand the search:
- PubMed search for NCT04536129
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Ocular Surface Disease
Currently open trials in the same condition.
- NCT07537426 — The Efficacy of Intradermal Acupuncture for Ocular Surface Diseases After Intractable Facial Paralysis · NA · recruiting
- NCT07502378 — Effect of Acoltremon Ophthalmic Solution 0.003% on Signs and Symptoms of Ocular Surface Disease in Stage I Neurotrophic · Phase 4 · recruiting
- NCT07297849 — Eyelid Closure in Keratometry · NA · recruiting
- NCT06555367 — Clinical Application Research of Scleral Lenses in Ocular Surface Diseases · recruiting
- NCT06355128 — A Cross-sectional Study of Ocular Manifestations During the Covid-19 Pandemic in Hubei Province · active not recruiting
Other University of Molise trials
Trials by the same sponsor.
- NCT06669598 — ENHANCING PHYSICAL and COGNITIVE EFFICIENCY in INDIVIDUALS AT RISK of DEMENTIA USING WHOLE-BODY ELECTROMYOSTIMULATION · NA · completed
- NCT06690853 — Effects of Coordinative Warm-Up Exercise Protocols on the Technical and Cognitive Performance of Soccer Players · NA · completed
- NCT06684808 — Impact of Active Breaks in Elementary School Children · NA · completed
- NCT07116044 — Assessment of Response and Safety of Bulevirtide Treatment in Patients With Chronic Delta Virus Infection · completed
- NCT04742855 — Probiotics for Blepharitis in Adults and Children · unknown
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04536129 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by University of Molise
- Last refreshed: 1 October 2021
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04536129.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing